Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 60,369 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 60,369 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $1.29, for a total transaction of $77,876.01. Following the sale, the director owned 3,943,359 shares of the company’s stock, valued at $5,086,933.11. This trade represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Friday, October 31st, Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total transaction of $93,685.76.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $133,538.70.
• On Tuesday, October 28th, Luke Evnin sold 44,327 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $72,696.28.
• On Monday, October 27th, Luke Evnin sold 46,664 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $80,262.08.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $1.31 on Tuesday. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.52. The company has a market cap of $59.91 million, a PE ratio of -0.80 and a beta of 0.73. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average of $1.62 and a two-hundred day moving average of $1.32.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. As a group, equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on HOWL shares. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Bank of America lowered their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities lowered their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Finally, Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HOWL. MPM Asset Management LLC grew its holdings in Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the period. MPM Bioimpact LLC grew its holdings in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the period. Bank of America Corp DE grew its holdings in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the period. Jane Street Group LLC acquired a new position in Werewolf Therapeutics during the second quarter valued at approximately $409,000. Finally, Marshall Wace LLP acquired a new position in Werewolf Therapeutics during the second quarter valued at approximately $113,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.